GenFleet Therapeutics

Focus: GenFleet Therapeutics is an oncology-focused biotech company developing small and large molecule therapeutics, based in Shanghai with a pipeline concentrated in solid tumors and hematologic malignancies. The company operates as a pre-revenue biotech with early-stage clinical programs.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About GenFleet Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow GenFleet Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

GFS202A injection

Cancer Cachexia

Phase 1

Clinical Trials (1)

NCT06898255A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia

Phase 1

Help build intelligence for GenFleet Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diverse oncology pipeline with 16 active clinical trials spanning Phase 1-3, including promising KRAS G12D and pancreatic cancer programs with Phase 3 potential
Exposure to emerging therapeutic modalities and cutting-edge cancer targets in a growth-stage organization with clear clinical progression
Shanghai headquarters provides access to Asian biotech ecosystem and emerging market expansion opportunities

Watch Out For

Zero active job openings at time of analysis signals either scaling pause or data lag, limiting immediate hiring visibility
Pre-revenue status with no disclosed funding or financial data creates significant uncertainty around runway and long-term stability
Early-stage pipeline (12 Phase 1, 1 Phase 3) with concentrated oncology focus means limited commercial infrastructure and product revenue diversification

Generated by Claude from GenFleet Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

GFH312 100 mg

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT05991362A Phase I Study of GFH312 in Healthy Chinese Subjects

Phase 1

GFH018

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT05051241A Study of GFH018 in Patients With Advanced Solid Tumors

Phase 1